EPISODE · Aug 12, 2026 · 28 MIN
Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
from Decera Clinical Education Oncology Podcast · host James A. Davis PharmD BCOP, Kelly L. Julian PharmD BCOP
In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including: Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters:James A. Davis, PharmD, BCOP Clinical Pharmacy Specialist, Myeloma/Lymphoma The Medical University of South Carolina, Hollings Cancer Center Affiliate Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Kelley L. Julian, PharmD, BCOP Hematology/BMT Pharmacy Supervisor PGY2 Oncology Pharmacy Residency Program Director Huntsman Cancer Institute, University of Utah Salt Lake City, Utah Link to full program: https://bit.ly/4qaRb7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
This podcast examines evidence guiding the use of anti-CD38–based therapy in smoldering and newly diagnosed multiple myeloma, including risk stratification, transplant eligibility, frailty, and measurable residual disease assessments. Pharmacists review findings from pivotal trials of daratumumab- and isatuximab-containing regimens, discuss triplet and quadruplet treatment strategies for transplant-eligible and transplant-ineligible patients, and consider the evolving roles of transplantation, maintenance therapy, and response-adapted care. The discussion also addresses pharmacist-led supportive care, toxicity prevention and management, dose modification, and subcutaneous anti-CD38 administration to support individualized treatment selection and safe, sustained therapy.
NOW PLAYING
Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.